clinical trial · NCT05987644
Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
Joshua Palmer·phase2·recruiting·n = 56
Lung CancerNSCLCBrain MetastasesAlectinibStereotactic Radiosurgery
brief summary
This study will consist of a Phase 1b and Phase 2 portion. The Phase 1b portion will enroll first followed by the Phase 2 portion. Each cycle of treatment = 28 days. Subjects will receive alectinib twice daily. Those in the Phase 1b portion will receive alectinib alone. Those in Phase 2 Arm A will receive alectinib alone. Those in Phase 2, Arm B will receive SRS + alectinib. A maximum of 25 cycles (2 years) of alectinib may be administered on study.
started
Mar 7, 2024
primary completion
Feb 28, 2028
completion
Feb 28, 2029
last updated
Apr 8, 2026
official title
DURABLE: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and rEarrangements
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol